Home/Rankings/Olympus Corporation

Olympus Corporation

7733.TMEDIUMScore: 49.6

Core — Endoscopy / Surgical Devices · Weight: 8%· Data as of 2026-05-04

Also in:Healthcare & Aging Society

Investment Thesis

~70% global share in GI flexible endoscopy — a near-monopoly in a medical device category that every hospital with a GI department must have. Co-invented the flexible endoscope 50+ years ago; proprietary optical, imaging, and AI integration (CADDIE polyp detection, OLYSENSE platform) creates technology moat no competitor has replicated. FY2025 adj FCF ¥109.4B on ~¥1.58T market cap = 6.9% FCF yield. The current revenue decline is a regulatory disruption (FDA Aizu import alert June 2025), NOT demand destruction — making this potentially a trough entry. Resolution is the key catalyst.

Risk

1) FDA import alert on Aizu facility (Fukushima) STILL ACTIVE as of May 2026 — CEO targeted resolution by March 2026 but FDA is still engaging. Full resolution timeline unknown. 2) Duodenoscope lawsuits: 2 patient deaths + 5 serious injuries reported; Class 1 recall on MAJ-891 accessory. 3) FY2026 revenue declining in both GI and Surgical segments (~1-5% YoY). Surgical & Interventional segment turned to operating LOSS (¥-10.6B vs +¥7.3B prior year) through Q3 FY2026. 4) Risk of FDA consent decree (more severe than import alert) if corrective actions are deemed inadequate.

Monitoring Trigger

If Olympus issues press release confirming FDA Aizu import alert lifted, ADD to 12% (resolution is primary re-rating catalyst). If FDA upgrades to consent decree, EXIT immediately (revenue impact would be sustained and structural). Watch FY2026 full-year results (expected late May/June 2026): if adj FCF holds above ¥90B, moat is intact. If Surgical & Interventional turns profitable again at Q1 FY2027, thesis confirmed.

Key Dates

2026-05earningsOlympus FY2026 full-year results (Mar 31 FY-end) — KEY: check if adj FCF held above ¥90B and whether FDA commitments progress is disclosed
2026-06monitoringFDA Aizu import alert status — watch for press release from Olympus confirming alert lifted. This is the single most important monitoring event.
2026-11earningsQ2 FY2027 — first full quarter with or without US Aizu restrictions; confirms revenue recovery trajectory

Key Metrics

22.98
PE
N/A
Fwd PE
3
P/B
N/A
ROE
18.9% (adj FY2025)
Op Margin
N/A
D/E
1.45%
Div Yield
+¥109B (adj FY2025)
FCF
~¥1.58T
Mkt Cap

Business Segments

SegmentRevenueShareDescription
Gastrointestinal Solutions
Surgical & Interventional Solutions
Global Services (Repair & Maintenance)

Supply Chain Evidence

EvidenceCustomerProductDetail
confirmedGlobal hospitals with GI endoscopy departments (190+ countries)Flexible GI endoscopes (gastroscopes, colonoscopes, duodenoscopes), EVIS X1 system~70% global GI endoscope market share. EVIS X1 with CADDIE AI polyp detection launched 2025. FDA clearance for EZ1500 series (May 2025).
confirmedEndoRobotics (global distribution target)Robot-assisted endotherapy technologies (EndoTherapy portfolio)Exclusive global distribution agreement signed May 2026. Olympus distributes EndoRobotics robot-assisted devices under its EndoTherapy brand.
confirmedMacroLux Medical Technology (global urology target)Single-use cystoscopes, ureteroscopes, suction access sheathsExclusive global distribution agreement Sep 2025 for single-use urology endoscopes.
confirmedCanon Medical Systems (collaborative development)Endoscopic Ultrasound System (EUS) — jointly developedCanon Medical + Olympus jointly developed EUS combining Canon ultrasound with Olympus endoscopy expertise.

Sources & References

↗↗↗↗↗↗